Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lipitor, Zocor and Pravachol Show Equal Rhabdomyolysis Risk – JAMA Article

This article was originally published in The Pink Sheet Daily

Executive Summary

The top three statins have a roughly equivalent risk of rhabdomyolysis, a study of health plan prescription data published in the Journal of the American Medical Association concludes

You may also be interested in...



FDA Drug Safety Initiative Is "Inadequate," JAMA Editorial Says

IoM study of drug safety system is "appropriate," but the "initial steps" proposed by FDA are not enough "to restore the trust and confidence necessary" for agency's public health mission. JAMA editors propose independent drug safety agency, with mandatory Phase IV studies.

Crestor, Serevent Are Among Problem Drugs Cited By FDA Safety Reviewer

FDA Office of Drug Safety personnel will be publishing a paper on statins and rhabdomyolysis in an upcoming issue of the Journal of the American Medical Association, Associate Director for Science David Graham told the Senate Finance Committee during a Nov. 18 hearing on Merck's withdrawal of Vioxx

Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal

A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel